Key result
Adeno-associated viral vectors demonstrate significant potential for personalized gene therapy in epilepsy by modulating neuropeptides, ion channels, and neurotrophic factors to reduce seizures.
Why the study?
A significant proportion of patients with epilepsy develop pharmacoresistance to antiepileptic drugs, necessitating the search for new therapeutic methods such as gene therapy.
Does the use of adeno-associated viral (AAV) vectors in gene therapy reduce seizure activity in patients with epilepsy?
Does the use of adeno-associated viral (AAV) vectors in gene therapy reduce seizure activity in patients with epilepsy?
AAV vectors offer a promising, personalized gene therapy approach for treating pharmacoresistant epilepsy by modulating various neural targets.
Answers are grounded in this paper and cite their sources.
AAV gene therapy for epilepsy should not yet change practice; leaves open the need for human efficacy and safety trials.
Epilepsy is a brain disorder characterized by a persistent predisposition to epileptic seizures. With various etiologies of epilepsy, a significant proportion of patients develop pharmacoresistance to antiepileptic drugs, which necessitates the search for new therapeutic methods, in particular, using gene therapy. This review discusses the use of adeno-associated viral (AAV) vectors in gene therapy for epilepsy, emphasizing their advantages, such as high efficiency of neuronal tissue transduction and low immunogenicity/cytotoxicity. AAV vectors provide the possibility of personalized therapy due to the diversity of serotypes and genomic constructs, which allows for increasing the specificity and effectiveness of treatment. Promising orientations include the modulation of the expression of neuropeptides, ion channels, transcription, and neurotrophic factors, as well as the use of antisense oligonucleotides to regulate seizure activity, which can reduce the severity of epileptic disorders. This review summarizes the current advances in the use of AAV vectors for the treatment of epilepsy of various etiologies, demonstrating the significant potential of AAV vectors for the development of personalized and more effective approaches to reducing seizure activity and improving patient prognosis.
No takes yet. Share an insight, caveat, or question.
Mullagulova et al. (2024) conducted a review in Epilepsy. Adeno-associated viral (AAV) vectors was evaluated. Adeno-associated viral vectors demonstrate significant potential for personalized gene therapy in epilepsy by modulating neuropeptides, ion channels, and neurotrophic factors to reduce seizures.
Synapse has enriched 10 related papers. Consider them for comparative context: